All News

Immunotherapy checkpoint inhibitors have changed the landscape of oncology treatment, however, they can come with a risk of adverse effects and, in rare cases, cause serious medical problems.

Atezolizumab (Tecentriq) approved by FDA in combination with bevacizumab (Avastin), carboplatin, and paclitaxel for the first-line treatment of metastatic nonsquamous non-small cell lung cancer.

Top news of the week from Specialty Pharmacy Times.

Specialty pharmacies offer a wide range of services vital to manufacturers and patients alike.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Onasemnogene abeparvovec (Zolgensma) is a 1-time infusion that replaces the defective or missing SMN1 gene with a functional copy.

HIV is not associated with preterm delivery, though antiretroviral therapy is, but hepatitis C may be a potential risk factor.

We know that burnout continues to plague health care professionals.

An analysis indicates that immune-related adverse events may be more common than initially reported in the clinical trials for these therapies.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Combination of azacitidine and nivolumab shows efficacy in patients with an average of 2 prior treatments for relapsed or refractory AML.

Detecting hepatitis C RNA in peripheral blood mononuclear cells or liver cells in patients who are negative for viral RNA raises questions about the risk of transmission to other individuals.

Just under one-fourth of all Americans have arthritis.

Are your business decisions putting money into your bank account?

These products are being recalled due to detected trace amounts of an impurity, N-nitrosodiethylamine (NDEA) contained in the API valsartan.

Phase 2 data show positive results for a therapy including 2 immune checkpoint inhibitors and chemotherapy.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Amifampridine is an oral, nonspecific, voltage-dependent, potassium channel blocker that causes depolarization of a presynaptic membrane and slows or inhibits repolarization.

Early detection is vital to more patients with hepatitis C virus being eligible for increasingly efficient direct-acting antiviral treatment options.

Safety data came from both phase 3 studies as well as a phase 2 study of Dextenza, which together totaled 351 patients.

The research, a part of AmerisourceBergen’s first-ever Pharmacy Check-Up: Activity & Barriers to Care Analysis, examined various pharmacy settings.

A phase 2 study demonstrated promising response rates and overall survival in patients with acute myeloid leukemia who were treated with azacitidine plus nivolumab.

Abeparvovec (Zolgensma) is a one-time infusion that replaces the defective or missing SMN1 gene with a functional copy that can create the SMN protein and prevent the loss of motor neurons in patients with spinal muscular atrophy.

Top news of the day from across the health care landscape.

FDA finds rare but serious risks of stroke and blood vessel wall tears associated with the multiple sclerosis drug alemtuzumab (Lemtrada).

Top news of the day from across the health care landscape.

Can you solve the pharmaceutical mystery? Each week, a new case study is presented.